As is well known, cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate production [38] and also contributed to 5-hydroxymethylcytosine depletion in cancer cells [39, 40]. The gene discussed is IDH1; the disease is cancer.